Philip S Rosenberg1, Kimberly A Barker2, William F Anderson2. 1. Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PSR, KAB, WFA). rosenbep@mail.nih.gov. 2. Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD (PSR, KAB, WFA).
Abstract
BACKGROUND: No study has predicted the future incidence rate and annual burden (number) of new cases in the United States of invasive and in situ female breast cancers stratified by the estrogen receptor (ER) status. METHODS: We constructed forecasts for women age 30 to 84 years in 2011 through 2030 using cancer incidence data from the Surveillance, Epidemiology, and End Results Program, novel age-period-cohort forecasting models, and population projections from the US Census Bureau. RESULTS: The total number of new tumors (invasive plus in situ) is expected to rise from 283 000 in 2011 to 441 000 in 2030 (plausible range 353 500 to 466 700 cases). The proportion of all new case patients age 70 to 84 years is expected to increase from 24.3% to 34.8%, while the proportion ages 50 to 69 years is expected to decrease from 54.7% to 43.6%. The proportion of ER-positive invasive cancers is expected to remain nearly the same at 62.6%, whereas the proportion of ER-positive in situ cancers is expected to increase from 19.1% to 28.9%. The proportion of ER-negative cancers (invasive and in situ) is expected to decrease from 16.8% to 8.6%. CONCLUSIONS: Breast cancer overall will rise in the United States through 2030, especially for ER-positive in situ tumors among women age 70 to 84 years. In contrast, ER-negative invasive and in situ tumors will fall, for reasons that are not fully understood. These results highlight a need to optimize case management among older women, characterize the natural history of in situ cancers, and identify those factors responsible for declining ER-negative incidence. Published by Oxford University Press 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: No study has predicted the future incidence rate and annual burden (number) of new cases in the United States of invasive and in situ female breast cancers stratified by the estrogen receptor (ER) status. METHODS: We constructed forecasts for women age 30 to 84 years in 2011 through 2030 using cancer incidence data from the Surveillance, Epidemiology, and End Results Program, novel age-period-cohort forecasting models, and population projections from the US Census Bureau. RESULTS: The total number of new tumors (invasive plus in situ) is expected to rise from 283 000 in 2011 to 441 000 in 2030 (plausible range 353 500 to 466 700 cases). The proportion of all new case patients age 70 to 84 years is expected to increase from 24.3% to 34.8%, while the proportion ages 50 to 69 years is expected to decrease from 54.7% to 43.6%. The proportion of ER-positive invasive cancers is expected to remain nearly the same at 62.6%, whereas the proportion of ER-positive in situ cancers is expected to increase from 19.1% to 28.9%. The proportion of ER-negative cancers (invasive and in situ) is expected to decrease from 16.8% to 8.6%. CONCLUSIONS:Breast cancer overall will rise in the United States through 2030, especially for ER-positive in situ tumors among women age 70 to 84 years. In contrast, ER-negative invasive and in situ tumors will fall, for reasons that are not fully understood. These results highlight a need to optimize case management among older women, characterize the natural history of in situ cancers, and identify those factors responsible for declining ER-negative incidence. Published by Oxford University Press 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Virginia L Ernster; Rachel Ballard-Barbash; William E Barlow; Yingye Zheng; Donald L Weaver; Gary Cutter; Bonnie C Yankaskas; Robert Rosenberg; Patricia A Carney; Karla Kerlikowske; Stephen H Taplin; Nicole Urban; Berta M Geller Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506
Authors: Limin X Clegg; Eric J Feuer; Douglas N Midthune; Michael P Fay; Benjamin F Hankey Journal: J Natl Cancer Inst Date: 2002-10-16 Impact factor: 13.506
Authors: Constance D Lehman; Constantine Gatsonis; Christiane K Kuhl; R Edward Hendrick; Etta D Pisano; Lucy Hanna; Sue Peacock; Stanley F Smazal; Daniel D Maki; Thomas B Julian; Elizabeth R DePeri; David A Bluemke; Mitchell D Schnall Journal: N Engl J Med Date: 2007-03-28 Impact factor: 91.245
Authors: Michelle D Althuis; Jennifer H Fergenbaum; Montserrat Garcia-Closas; Louise A Brinton; M Patricia Madigan; Mark E Sherman Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-10 Impact factor: 4.254
Authors: Graham A Colditz; Bernard A Rosner; Wendy Y Chen; Michelle D Holmes; Susan E Hankinson Journal: J Natl Cancer Inst Date: 2004-02-04 Impact factor: 13.506
Authors: Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry Journal: N Engl J Med Date: 2007-04-19 Impact factor: 91.245
Authors: Sylvia K Plevritis; Diego Munoz; Allison W Kurian; Natasha K Stout; Oguzhan Alagoz; Aimee M Near; Sandra J Lee; Jeroen J van den Broek; Xuelin Huang; Clyde B Schechter; Brian L Sprague; Juhee Song; Harry J de Koning; Amy Trentham-Dietz; Nicolien T van Ravesteyn; Ronald Gangnon; Young Chandler; Yisheng Li; Cong Xu; Mehmet Ali Ergun; Hui Huang; Donald A Berry; Jeanne S Mandelblatt Journal: JAMA Date: 2018-01-09 Impact factor: 56.272
Authors: Joseph E Tota; Ana F Best; Zachary S Zumsteg; Maura L Gillison; Philip S Rosenberg; Anil K Chaturvedi Journal: J Clin Oncol Date: 2019-04-26 Impact factor: 44.544
Authors: Armen A Ghazarian; Scott P Kelly; Sean F Altekruse; Philip S Rosenberg; Katherine A McGlynn Journal: Cancer Date: 2017-02-27 Impact factor: 6.860
Authors: Brittny C Davis Lynn; Philip S Rosenberg; William F Anderson; Gretchen L Gierach Journal: J Natl Cancer Inst Date: 2019-01-01 Impact factor: 13.506
Authors: Brittny C Davis Lynn; Philip S Rosenberg; William F Anderson; Gretchen L Gierach Journal: J Natl Cancer Inst Date: 2018-11-01 Impact factor: 13.506
Authors: Ana F Best; Emily A Haozous; Amy Berrington de Gonzalez; Pavel Chernyavskiy; Neal D Freedman; Patricia Hartge; David Thomas; Philip S Rosenberg; Meredith S Shiels Journal: Lancet Public Health Date: 2018-07-21
Authors: Gonçalo Forjaz de Lacerda; Scott P Kelly; Joana Bastos; Clara Castro; Alexandra Mayer; Angela B Mariotto; William F Anderson Journal: Cancer Epidemiol Date: 2018-03-13 Impact factor: 2.984